Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders. On April 30, 2010, the company received a complaint filed by Celgene Corporation seeking a declaration from the court that 4 Cyclacel-owned patents, which claim the use of romidepsin injection in T-cell lymphomas, are not infringed by Celgene’s products and is invalid. Today, Cyclacel filed its Answer and Counterclaims to this declaratory judgment complaint filed by Celgene Corporatoin. It has filed counterclaims charging Celgene’s infringement as well as injunctive relief. The 4 patents directly involve the use and administration of Celgene’s ISTODAX ® (romidepsin for injection) product.
The declaratory judgment complaint seeks to have the 4 Cyclacel patents, which claim the use of romidepsin for injection in T-cell lymphomas, declared invalid and not infringed by Celgene’s products. The 4 Cyclacel patents which are the subject of this action do not involve Cyclacel’s clinical development candidates or its commercial products.
Disclosure: no positions